+1-646-568-9980, +44-203-287-6050
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
global epilepsy drugs market

Global Epilepsy Drugs Market Size, [By Drug Type (First Generation Drugs, (Phenytoin, Carbamazepine, Oxycarbazepine, Valproate), Second Generation Drugs (Levetiracetam, Lamotrigine, Topiramate, Pregabalin), and Third Generation Drugs (Lacosamide, Perampanel)]; and Geography - Trend, Analysis and Forecast till 2025

Published: Jun 2018
Pages: 0
Format: PDF
Report ID: PM1315
License and Pricing
Buy Now Inquire Before Buying

Report Summary

The Global Epilepsy Drugs Market Size is anticipated to generate remarkable growth due increasing need of proper treatment with growing incidences of neurological disorders. Epilepsy also known as seizure disorder is a neurological disease marked by abrupt repeated incidents of sensual disturbance, loss of realization or awareness regarding nearby activities, and convulsions, associated with abnormal electrical activity in the cells of the brain. Epilepsy arises owing to a medical injury or condition that affects the brain cells, or the cause may be idiopathic and sometimes unknown. General causes of epilepsy include distressing brain injury, brain stroke head injury happened during or at a timed birth. The type of these disorder depends on the part of the brain affected and cause of epilepsy. Epilepsy shows one or more type of seizure and with additional symptoms of neurological ailments. The specific type of epilepsy syndrome shows similar indications with the different group of people. Past clinical history, EEG testing, and family background are the reasons for this type of syndrome.

The brain is the major source of epilepsy even though the indications of seizure disorder can affect any body part. A huge number of the population suffer epilepsy globally. According to the World Health Organization (WHO) reports, globally around 50 million people suffer from epilepsy and this number is still on the surge. Epilepsy may not get cured perfectly, but through the proper medication and the treatment, the disorder may possibly get controlled.

The awareness programs creating welfare of drugs and efforts by key players to form advanced drugs is boosting the global epilepsy drugs market size.

The global epilepsy drugs market size is driven by the presence of a large patient pool and the growing occurrence of neurological disorders. According to the World Health Organization (WHO) In 2013, approximately 750,000 children aged 0-17 years and 4.3 million adults were diagnosed to have epilepsy throughout the globe. The number of people suffering epilepsy is still on the rise. Thus rising prevalence demanding for epilepsy drugs such as Stedesa, Sunovion, Trobalt, Potig, and Zebinix, is anticipated to fuel the epilepsy drugs market.

Moreover, the rising attentiveness for epilepsy coupled with deliberate associations is expected to boost the market growth. Various consciousness initiatives via epilepsy treatment programs and associations have directed to a rise in demand for better treatments and effective diagnosis of the disease. For instance, Anita Kaufmann Foundation and the Epilepsy Association of Nova Scotia announced March 26 as the “International Purple Day” in 2009 to enhance the global alertness regarding epilepsy and its drugs.

In addition, higher incidence of birth-related brain injuries, increasing R&D investment, increasing disease awareness and the welfare related drugs, the launch of extended-release formulations, and rising patient pool in developing countries are another major factors driving the global Epilepsy drugs market.

However, unavailability or minimal availability of Epilepsy drugs in low and middle-income countries such as some African Countries and the high cost of patented drugs might hamper the global epilepsy drugs market growth.

Global Epilepsy Drugs Market Size Taxonomy:

The global epilepsy drugs market is segmented on the basis of drug type and geography.

On the basis of drug type, the global epilepsy drugs market is segmented into:

  • First Generation Drugs
    • Phenytoin
    • Carbamazepine
    • Oxycarbazepine
    • Valproate
  • Second Generation Drugs
    • Levetiracetam
    • Lamotrigine
    • Topiramate
    • Pregabalin
  • Third Generation Drugs
    • Lacosamide
    • Perampanel

Geographically, the global epilepsy drugs market is segmented into North America, Europe, Asia pacific, Latin America, Middle East, and Africa.

Increased healthcare expenditures with government support and advancement in medical technology generating novel drugs are creating remarkable market growth in North America

In terms of geography, North America is estimated to dominate the global epilepsy drugs market. The availability of favorable government expenditures, widespread research and development initiatives by key investors, and the launch of the novel as well as innovative epileptic drugs controlling the disease are the factors propelling the growth of epilepsy market in this region. However, Asia Pacific is anticipated to form a dominating growth during the forecast period. The rising patient pool requiring proper medication for epilepsy and the rising awareness for the effective diagnosis and treatment of this disorder is anticipated to propel the epilepsy drugs market growth significantly. In addition, increased level of medical tourism, rising occurrence of epilepsy and the existence of high-unmet medical needs in emerging economies of India and China.

Key players of global epilepsy drugs market size:

  • Pfizer, Inc.
  • Eisai Co., Ltd
  • Novartis AG
  • Sanofi S.A.
  • UCB S.A.
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
Key Take-Away